MSI-H/DMMR COLORECTAL CANCER
Clinical trials for MSI-H/DMMR COLORECTAL CANCER explained in plain language.
Never miss a new study
Get alerted when new MSI-H/DMMR COLORECTAL CANCER trials appear
Sign up with your email to follow new studies for MSI-H/DMMR COLORECTAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to outsmart aggressive colon cancer
Disease control Recruiting nowThis phase 3 trial is testing whether adding the immunotherapy drug AK104 (cadonilimab) before and after surgery can improve outcomes for people with a specific type of colon cancer (MSI-H/dMMR). About 386 participants will be randomly assigned to receive either AK104 plus standa…
Matched conditions: MSI-H/DMMR COLORECTAL CANCER
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for advanced cancers: experimental drug EIK1005 enters human trials
Disease control Recruiting nowThis study tests a new drug called EIK1005, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug shrinks tumors. About 160 adults with certain cancer types…
Matched conditions: MSI-H/DMMR COLORECTAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC